Abstract Introduction: The therapeutic arsenal for Inflammatory Bowel Disease (IBD) has grown in recent years. Interleukin-23 (IL-23) p19 subunit inhibitors represent an emerging therapy for these patients. Risankizumab is an IL-23 inhibitor approved for the treatment of patients with moderate to severe Crohn's disease (CD). Objectives: To evaluate the effectiveness, survival, and short- and long-term safety of risankizumab in patients with Crohn’s disease (CD). Methods: Retrospective, multicenter, observational study of Crohn's disease patients from the Virgen de la Victoria University Hospital and the Regional University Hospital of Málaga treated with risankizumab. The primary endpoint was the clinical remission rate, calculated using the Harvey Bradshaw (HBI) clinical index. Results: A total of 51 patients were included. Clinical remission rates at 12, 26, and 52 weeks were 43.1%, 45.1%, and 49%, respectively. The median duration of treatment was 18 months, with a 12-month survival rate of 84% and a 24-month survival rate of 75%. Only one patient experienced treatment-related side effects requiring discontinuation. Conclusion: In this cohort of patients from routine clinical practice, risakizumab treatment was effective in inducing and maintaining remission, with a good safety profile.
Martínez et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: